Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193087 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,002
- Enrollment target
NCT02193087 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 1,002 participants.
The verdict
NCT02193087, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,002 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the equivalence of the lyophilized formulation of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) compared with the liquid formulation of TDV.
Interventions
- DRUG Placebo
- DRUG TDV Liquid Formulation 1
- DRUG TDV Liquid Formulation 2
- DRUG TDV IDT Lyophilized
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2014-08-06 |
| Est. Completion | 2015-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193087
The ClinicalTrials.gov registry entry for NCT02193087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,002 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02193087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02193087 about?
NCT02193087 is a clinical study titled "Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)". The purpose of this study is to evaluate the equivalence of the lyophilized formulation of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) compared with the liquid formulation of TDV.
What is the current status of trial NCT02193087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,002 participants. The study started on 2014-08-06. Estimated completion is 2015-05-19.
What interventions are being tested in trial NCT02193087?
The interventions under investigation include: Placebo (DRUG), TDV Liquid Formulation 1 (DRUG), TDV Liquid Formulation 2 (DRUG), TDV IDT Lyophilized (DRUG).
Who is sponsoring clinical trial NCT02193087?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.